Tedatioxetine (Lu AA24530) is an antidepressant currently under development by Lundbeck and Takeda for the treatment of major depressive disorder (MDD). Tedatioxetine is reported to act as a triple reuptake inhibitor (5-HT > NE > DA) and in addition as a 5-HT2A 5-HT2C 5-HT3 and α1A-adrenergic receptor antagonist. It is currently in Phase II of clinical trials.
This page contains content from the copyrighted Wikipedia article "Tedatioxetine"; that content is used under the GNU Free Documentation License (GFDL). You may redistribute it, verbatim or modified, providing that you comply with the terms of the GFDL.
